Last Updated: May 2, 2026

CLINICAL TRIALS PROFILE FOR FENTORA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Fentora

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00387010 ↗ Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain Terminated Cephalon Phase 3 2006-12-01 The primary purpose of the study is to evaluate the impact of treatment with fentanyl buccal tablets on the anxiety symptoms commonly associated with chronic pain in patients with breakthrough pain (BTP). Other purposes are to assess the management of BTP, to evaluate patient functioning, and to determine any influences on the successful dose achieved.
NCT00685295 ↗ Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain Completed Massachusetts General Hospital Phase 1/Phase 2 2008-08-01 Assess whether transbuccal fentanyl provides more rapid relief of orthopedic pain, than does the comparator Percocet
NCT00842829 ↗ Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients Terminated Cephalon Phase 4 2009-01-01 Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. Fentanyl Buccal Tablet (FBT) is used for the treatment of BTP in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. FBT treatment should be individually titrated to an effective dose that provides adequate analgesia and minimizes undesirable effects. To reach the safest effective dose for the individual patient as soon as possible, the dose titration process is critical. The aim of this study, conducted under pragmatic conditions in a large-scale population of cancer patients is to compare the proportion of patients reaching an effective FBT dose after titration starting with either a 100 mcg dose or a 200 mcg dose.
NCT01007773 ↗ Safety of Dexmedetomidine in Severe Traumatic Brain Injury Withdrawn Hospira, Inc. Phase 2 2010-01-01 The aim of this study is to assess the safety and feasibility of dexmedetomidine as an adjunct to conventional sedative therapy compared to conventional sedative therapy alone in patients with severe traumatic brain injury.
NCT01007773 ↗ Safety of Dexmedetomidine in Severe Traumatic Brain Injury Withdrawn Hospira, now a wholly owned subsidiary of Pfizer Phase 2 2010-01-01 The aim of this study is to assess the safety and feasibility of dexmedetomidine as an adjunct to conventional sedative therapy compared to conventional sedative therapy alone in patients with severe traumatic brain injury.
NCT01007773 ↗ Safety of Dexmedetomidine in Severe Traumatic Brain Injury Withdrawn University of Maryland Phase 2 2010-01-01 The aim of this study is to assess the safety and feasibility of dexmedetomidine as an adjunct to conventional sedative therapy compared to conventional sedative therapy alone in patients with severe traumatic brain injury.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fentora

Condition Name

Condition Name for Fentora
Intervention Trials
Breakthrough Pain 2
Pain 2
Hemorrhage, Intracranial 1
Stroke 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fentora
Intervention Trials
Breakthrough Pain 2
Brain Injuries, Traumatic 1
Hemorrhage 1
Pain, Postoperative 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fentora

Trials by Country

Trials by Country for Fentora
Location Trials
United States 30
Germany 1
Poland 1
France 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fentora
Location Trials
Pennsylvania 3
Utah 2
Texas 2
Illinois 2
Georgia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fentora

Clinical Trial Phase

Clinical Trial Phase for Fentora
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fentora
Clinical Trial Phase Trials
Completed 3
Withdrawn 3
Recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fentora

Sponsor Name

Sponsor Name for Fentora
Sponsor Trials
Hospira, now a wholly owned subsidiary of Pfizer 3
Hospira, Inc. 3
University of Pennsylvania 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fentora
Sponsor Trials
Other 11
Industry 8
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Fentora (fentanyl buccal) — Clinical Trial Update, Market Analysis, and 2026-2031 Projection

Last updated: April 27, 2026

What is Fentora and how is it positioned?

Fentora is a fentanyl citrate product delivered buccally for breakthrough cancer pain (BTcP) in opioid-tolerant patients. The product is branded and marketed by Jazz Pharmaceuticals in multiple major markets, with the commercial narrative centered on BTcP efficacy, rapid onset, and buccal delivery.

Indication (core commercial scope): BTcP in adults with cancer who are already receiving and are tolerant to opioid therapy. (EMA SmPC for fentanyl buccal products; label language is consistent across key jurisdictions: FDA label for Fentora and EU SmPC language).

How does the clinical development pipeline look right now?

A “clinical trials update” for Fentora specifically requires current, product-level trial activity. In the available record used for this update, there is no current, clearly attributable Fentora product trial program (new pivotal Phase 3/Phase 2 registrations or active product-defining studies) that can be stated with precision at the level required for actionable market forecasting.

What can be stated from an evidence-based market view is that fentanyl buccal products face a sustained competitive environment where formulation lifecycle work, line extensions, and comparative studies typically matter less than label scope, payer position, and substitution dynamics.

Clinical take: Fentora’s near-term trajectory is driven more by commercial execution and substitution pressure than by new product-shaping late-stage trials.

What is the competitive landscape for BTcP fentanyl buccal products?

Fentora competes in the BTcP fentanyl space, where payers and hospitals apply strict opioid risk management and choose among available fentanyl formulations based on:

  • Dosing flexibility and titration experience
  • Formulary placement and prior authorization requirements
  • Patient out-of-pocket cost
  • Availability of manufacturer support programs
  • Perceived onset profile and real-world ease of use

In the broader BTcP market, fentanyl products include:

  • Buccal fentanyl products (including Fentora and other branded comparators depending on geography and formulation)
  • Intranasal fentanyl options in multiple markets
  • Other opioid BTcP mechanisms (non-fentanyl options exist, depending on country)

The market outcome depends on payer behavior rather than on single clinical endpoints, because BTcP products are clinically similar within label class constraints and differentiation tends to be marginal at scale.

How big is the BTcP market for fentanyl and where does Fentora sit?

Fentanyl BTcP is a significant segment within cancer pain management, with demand supported by:

  • high prevalence of cancer pain,
  • established opioid-tolerant criteria,
  • and continued use once patients achieve a stable breakthrough regimen.

Fentora’s share is constrained by:

  • substitution from other fentanyl BTcP forms,
  • generic and authorized alternative dynamics in certain regions,
  • and payer preference for contracted products.

Because this request requires projection-quality sourcing at the product level, this update focuses on a scenario-based forecast built from market mechanics (class-level growth plus share erosion from substitution) rather than presenting speculative point estimates without direct evidence.

2026-2031 Market Projection for Fentora

Projection framework

This forecast treats Fentora performance as the sum of:

  1. Class growth in BTcP fentanyl (driven by durable diagnosis base and continued opioid access under risk programs)
  2. Share pressure from alternative fentanyl formulations and payer-driven substitution
  3. Pricing and mix effects (contracting, rebates, and channel dynamics)

Base case (commercially conservative)

  • Market growth: modest single-digit annual expansion for BTcP fentanyl due to steady patient population and stable adoption of BTcP fentanyl.
  • Fentora share: gradually declines as prescribers and payers select alternatives that achieve better access economics or smoother titration workflows.
  • Net revenue growth: low to mid single digits initially, then compresses as share pressure offsets class growth.

Downside case (substitution accelerates)

  • Faster switching to intranasal fentanyl or other contracted BTcP products.
  • More aggressive payer formulary tightening (higher prior authorization friction or stronger step therapy).
  • Net revenue growth turns flat or declines in later years.

Upside case (formulary stabilization)

  • Stronger payer contracting and patient support reduce switching.
  • Better persistence among titrated patients.
  • Net revenue growth stays near class growth without meaningful share loss.

What drives Fentora demand month-to-month?

Key demand levers in BTcP fentanyl include:

  • Patient persistence after titration: stable responders keep buying if access remains.
  • Payer controls: prior authorization, quantity limits, and formulary tiers.
  • Channel inventory and wholesaler purchasing patterns: particularly important around contracting cycles.
  • Risk mitigation compliance: restricted distribution and adherence to opioid REMS-like processes.

These are commercial forces that can swing quarterly performance even when clinical demand is stable.

Economic and policy forces shaping forecasts

Pricing and reimbursement

BTcP opioids are heavily rebated with contract and volume discounts. Forecasting must account for:

  • payer mix changes between public and commercial plans,
  • rebate rate evolution,
  • and geographic contracting differences.

Opioid regulatory environment

Regulatory scrutiny for fentanyl products affects:

  • prescriber requirements,
  • dispensing and inventory controls,
  • and payer willingness to keep lower-tier alternatives off formulary.

These forces tend to standardize product requirements rather than eliminate demand, so they affect mix and share more than they reduce class volume.

Risk profile for investors and R&D planners

  • Share erosion risk: continued substitution within BTcP fentanyl formulations.
  • Patent and exclusivity milestones: branded BTcP products can face authorized generic/authorized alternatives depending on jurisdiction and regulatory pathway.
  • Utilization management: higher access friction can shift volumes even when patient need remains.

What should a business plan assume for R&D near-term?

Given the absence of an evidence-ready, product-specific late-stage clinical update in the available record, a practical planning assumption is:

  • Fentora investment focus is on commercial life-cycle execution (access, contracting, patient support) and comparative evidence that strengthens formulary position.
  • New development is less likely to be pivotal for near-term revenue than to support defensibility against substitution.

Key Takeaways

  • Fentora targets BTcP in opioid-tolerant cancer patients via buccal fentanyl delivery.
  • A product-specific, current late-stage clinical trial update for Fentora cannot be validated at a projection-grade level from the available record used here.
  • Near-term performance is driven primarily by persistence after titration, payer contracting, and substitution across fentanyl BTcP formulations, not by new pivotal evidence.
  • 2026-2031 projection range: low-to-mid single digit growth in a base case, with flat-to-downside outcomes if substitution accelerates and formulary access tightens.

FAQs

1) Is Fentora still used for opioid-tolerant cancer patients with breakthrough pain?
Yes. The core labeled indication remains breakthrough cancer pain in opioid-tolerant adults receiving baseline opioid therapy.

2) What most influences Fentora revenue beyond clinical performance?
Formulary tier placement, prior authorization requirements, rebate contracting, and patient persistence after titration.

3) Does substitution risk come mainly from intranasal fentanyl products?
Substitution is primarily within the BTcP fentanyl class, including intranasal formulations and other contracted fentanyl options depending on market and formulary.

4) What does the forecast assume about growth in the BTcP fentanyl class?
The base case assumes modest single-digit class growth supported by the stable patient need for BTcP therapy and continued adoption under opioid risk controls.

5) What is the most important near-term action for stakeholders?
Monitor formulary changes and contracting outcomes because share erosion or stabilization will dominate net revenue trends over new clinical updates.


References (APA)

[1] European Medicines Agency. Fentora (fentanyl buccal tablets) product information (summary of product characteristics). EMA.
[2] U.S. Food and Drug Administration. Fentora (fentanyl buccal tablets) prescribing information. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.